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ABSTRACT
Aim: Women with polycystic ovary syndrome (PCOS) often have elevated levels of the andro-
gen testosterone, and are at increased risk of anxiety and depression. This study aimed to use 
psychological relaxation with guided imagery to decrease androgen levels and improve mood 
in PCOS. Methods: Repeated-measures. Thirteen women with PCOS underwent six weekly 
treatment sessions, and a follow-up session, of calming breathing, muscle relaxation, and 
guided imagery. The main outcome measures were mood and quality of life (QoL) – assessed 
using validated questionnaires – and hormones, which were assayed in serum using tandem 
mass spectrometry. Results: There was a small but statistically significant reduction in DHEAS 
from before to after Week 1 (p <.044) and from before to after Week 6 (p <.001). From before 
to after Week 6 there were also small but statistically significant reductions in androstenedi-
one (p <.010) and cortisol (p <.003). From Week 1 to Week 6 there was a significant reduc-
tion in anxiety (p <.037). There was a significant improvement in depression from Week 1 to 
Week 6 (p <.034) and from Week 1 to follow-up (p <.011). There were no significant changes 
in free or total testosterone, nor in QoL. Conclusions: This is the first study to use a relaxation 
programme to reduce adrenal androgens in PCOS.
Keywords: Relaxation; androgen; depression; anxiety; polycystic ovary syndrome.
INTRODUCTION
Polycystic ovary syndrome (PCOS) is a condition affecting 8% to 17% of women aged 20 
to 40 years old (Lauritsen et al., 2014). One of the diagnostic features of PCOS is elevated 
testosterone levels. Testosterone and other biochemicals of the androgen family (such as 
dehydroepiandrosterone sulfate (DHEAS) and androstenedione) contribute to the distressing 
physical symptoms of PCOS (infertility, acne, hirsutism, and obesity).
Women with PCOS are more at risk of anxiety and depression (Barry et al., 2011), cancer 
(Barry et al., 2014), and coronary heart disease and stroke (Anderson et al., 2014). The 
economic burden of PCOS in the United States is at least $13.9 billion annually (Azziz, 2008).
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For many women with PCOS, the symptoms of excess androgen levels, such as hirsutism, 
are distressing. Although hirsutism is often attributed to testosterone, the correlation 
between testosterone and hirsutism is not strong (r = 0.24 at best; Legro et al., 2010), 
suggesting the contribution of other androgens to hirsutism too. Psychological factors can 
activate the adrenal glands, and adrenal activation stimulates not only cortisol production but 
androgen secretion (Leowattana, 2004). Women with PCOS may show evidence of adrenal 
hyperresponsivity to adrenocorticotropic hormone (ACTH), leading to increased DHEAS levels 
(McKenna & Cunningham, 1995; Milutinovi et al., 2011; Moran et al., 2004). Thus there may 
be something of a vicious circle, in which adrenal androgens contribute to the distressing 
symptoms of PCOS, and distress in reaction to the symptoms might lead to an increase in 
adrenal androgens.
Psychological relaxation techniques can non-pharmacologically reduce hypothalamic-
pituitary axis (HPA) activity, alleviate anxiety and depression, and improve QoL and well-being 
(Deng & Cassileth, 2005). Relaxation is known to lower cortisol levels, but the evidence that 
relaxation can lower androgen levels is less clear, for example Cruess and colleagues (2001) 
found that stress-management significantly reduced free and total testosterone in breast 
cancer patients, whereas Carlson and colleagues (2004) found only a non-significant reduction 
in DHEAS levels. Few studies have used interventions to improve mood in PCOS, but a recent 
study of mindfulness training found a significant reduction in cortisol, stress and depression, 
though no improvement in QoL (Stefanaki et al., 2014).
The aim of the present study was to assess the effect of psychological relaxation and 
guided imagery on psychological functioning (anxiety, depression, and QoL) and hormone 
levels (DHEAS, androstenedione, cortisol, and testosterone) in women with PCOS.
MATERIALS AND METHODS
PARTICIPANTS
Participants were 13 women, aged between 19 and 33 years old, with a diagnosis of PCOS by 
the Rotterdam criteria, attending two reproductive endocrinology clinics in London teaching 
hospitals. Patients were also recruited from the researchers’ website (www.PCOSresearch.
org). Eleven participants completed the programme.
DESIgN
This study used a repeated measures design. Participants were recruited from October 2012 
to May 2013, and participated in two consecutive cohorts between May and August 2013. 
Hormone levels and mood questionnaires were the outcome variables and were measured 
at baseline, at the final treatment session, and at follow-up (~3 months after their final 
session).
MEASuRES
The biochemical outcomes measured were DHEAS, androstenedione, cortisol, and testosterone. 
Sex hormone-binding globulin (SHBG) was also measured in order to calculate the amount of 
bioavailable testosterone (the free androgen index, FAI). Blood samples were taken before 
and after the first, sixth, and the follow-up treatment session. To minimize any potential 
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influence of circadian rhythms, all participants were seen between 5.30pm and 8.30pm, and 
each participant had their treatment session scheduled at approximately the same time of 
day on each occasion. The mean (SD) duration between taking the pre and post session blood 
sample was 48 (13.2) minutes.
The psychological outcome measures were the PCOS Health-Related Quality of Life 
Questionnaire (PCOSQ) and the anxiety and depression subscales of the Hospital Anxiety and 
Depression Scale (HADS).
ASSAy METHODOLOgy
DHEAS, testosterone and androstenedione, and cortisol were assayed using liquid 
chromatography–mass spectrometry (LC–MS), to validated FDA guidelines. SHBG was 
measured using chemiluminescent microparticle immunoassay (CMIA) on the ARCHITECT 
i2000SR System (Abbott Diagnostics, Maidenhead, UK).
QuESTIONNAIRES
The PCOS Health-Related Quality of Life Questionnaire (PCOSQ). Thirty items assess feelings 
about symptoms of PCOS in the dimensions of emotions, hirsutism, obesity, infertility, 
menstruation, and acne. Lower scores indicate worse QoL.
The Hospital Anxiety and Depression Scale (HADS). Fourteen items measure state anxiety 
and depression. Scores of 8–10 indicate a mild problem; 11–14 moderate; 15–21 indicates a 
clinical problem.
Background data included body mass index (which may be related to androgen levels and 
depression) and demographic details. The Recent Life Changes Questionnaire was used as a 
control measure of stressful life events, measured in life change units (LCUs). Participants 
were offered debriefing interviews.
PROCEDuRE
PCOS patients were recruited from clinics at the Royal Free London Hospital, University College 
London Hospital and the researchers’ website. Volunteers were contacted and screened by NL, 
a counselling psychologist.
Psychological and hormonal measurements were done on each of the three measurement 
occasions (Weeks 1, 6 and follow-up). Serum samples were taken twice on each measurement 
day, once immediately before and once immediately after the intervention. All samples were 
centrifuged within two hours and stored at –80° until being analysed at the Department of 
Clinical Biochemistry, Manchester Hospital, Manchester, United Kingdom.
TREATMENT PROTOCOL
The psychological intervention took place in a quiet treatment room in the Gynaecology 
Clinic at the Royal Free London Hospital. Over six consecutive weeks, participants experienced 
individual relaxation therapy for 15 minutes at each session. The sessions included 
diaphragmatic breathing, progressive muscle relaxation, and visualization. The visualization 
was guided towards imagining positive images and feelings regarding whatever aspects of 
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PCOS were important to each participant. After each session, NL reviewed progress and 
encouraged brief relaxation and visualization exercise at home.
ETHICAL APPROVAL
This study was done with the approval of the London-Stanmore Research Ethics Committee 
(reference 12/LO/1529). Written informed consent was given by all the patients prior to the 
start of the study.
STATISTICAL ANALySIS
Comparisons across measurement occasions were made using repeated-measures t-tests. 
Correlations were measured using Pearson’s r. Categorical data were analysed using χ2 or 
Fisher’s exact tests. Where a directional hypothesis was made and supported by the findings, 
p values are stated as one-tailed. The threshold for statistical significance was p < .05. The 
software package SPSS Version 22 for Windows (Armonk, NY: IBM Corp) was used for statistical 
analyses.
RESULTS
Eleven of the 13 participants completed the programme. Table 1 shows baseline characteristics 
of the participants.
Table 1. Baseline characteristics of the participants who started the programme (n  = 13) and 
those who completed the programme (n  = 11). Two dropped out after the first session.
Demographic variable Participants 
(including dropouts) 
(n =13)
Participants 
(excluding dropouts) 
(n =11)
Age Mean (SD) 27.23 (4.68) 27.09 (4.59)
BMI Mean (SD) 26.00 (6.91) 26.55 (7.49)
Menstrual cycle Oligomenorrheic 62% (n = 8) 64% (n = 7)
Amenorrheic 23% (n = 3) 18% (n = 2)
Normal 15% (n = 2) 18% (n = 2)
Socioeconomic classa Managerial 42% (n = 5) 40% (n = 4)
Intermediate 16% (n = 2) 20% (n = 2)
Manual 42% (n = 5) 40% (n = 4)
Ethnicity
Caucasian 77% (n = 10) 82% (n = 9)
Asian 15% (n = 2) 9% (n = 1)
Mixed race 8% (n = 1) 9% (n = 1)
a Socioeconomic class not reported by one participant
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Some of the participants who completed the programme were taking medication throughout 
the programme and had been on this medication for some time. Four (36%) were taking 
combined oral contraceptives (n = 1 cyproterone acetate and ethinylestradiol; n = 1 ethinyl 
estradiol + drospirenone; n = 2 ethinylestradiol and levo norgestrel), two (18%) were taking 
metformin, one (9%) was taking thyroxin, one (9%) was taking venlafaxine, and three (28%) 
were not taking any relevant medication. In most cases the women were on these medications 
for a period of years before starting the programme. Thus any effects of medication were very 
likely stable, and the impact of these drugs on hormones and psychological outcomes would 
have been consistent on all measurement occasions.
HORMONE LEVELS
Table 2 shows that there was a significant reduction in DHEAS comparing pre and post Week 1 
(t = 1.921, d.f. = 9, p < 0.044) and pre Week 6 to post Week 6 (t = 4.301, d.f. = 10, p < 0.001). 
There was also a significant reduction in androstenedione (t = 2.766, d.f. = 10, p < 0.010), and 
cortisol (t = 3.521, d.f. = 10, p < 0.003) pre Week 6 to post Week 6. There was no change in 
free or total testosterone.
PSyCHOLOgICAL FuNCTIONINg
Table 2 shows that from Week 1 to Week 6 there was a significant reduction in anxiety (t 
= 2.01, d.f. = 10, p < 0.037) and depression (t = 2.10, d.f. = 10, p < 0.034). There was also a 
significant reduction in depression from Week 1 to Week 6 (t = 2.05, d.f. = 7, p < 0.034) and 
from Week 1 to 3 months follow-up (t = 2.34, d.f. = 8, p < 0.024). There was a non-significant 
improvement in QoL from Week 1 to Week 6. There was no significant relationship between 
outcomes and the type of medication being taken, nor between outcomes and the stressful 
life event scores of participants.
Two women dropped out after the first session; one participant did not appear to show any 
response to the treatment and the other said she didn’t think that the programme was suitable 
for her. To adjust for the effect of dropout, an intention-to-treat (ITT) analysis was done using 
the baseline-observation-carried-forward (BOCF) method. All 13 participants who started the 
programme were included, carrying forward their baseline scores as their follow-up scores. There 
were no significant changes in outcomes in the BOCF analysis compared to the findings in Table 2.
DEBRIEFINg INTERVIEWS
Two participants who completed the six sessions agreed to be interviewed. They both said that 
they felt good after the sessions (‘refreshed’, ‘happier and calmer’), and that the experience 
was very positive and helpful.
DISCUSSION
The results of this study lend support to our hypothesis that a psychological intervention 
can produce significant improvements in hormone and mood outcomes. The three adrenal 
hormones measured, DHEAS, androstenedione and cortisol, were all significantly reduced 
from pre Week 6 to post Week 6.
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In contrast to the present study, Cruess and colleagues (2001) found that both free and 
total testosterone levels were significantly decreased in women with early-stage breast cancer 
diagnosis randomized to a ten-week cognitive-behavioural stress management (CBSM) group. 
Our findings regarding psychological functioning reflect those of Stefanaki and colleagues 
(2014), who found improvements in stress (measured in the present study as anxiety) and 
depression. As for those researchers, the present study found no significant improvement 
in PCOS QoL. The QoL findings in both studies suggest that the psychological intervention, 
although having an impact on mood and adrenal hormones, did not have a significant impact 
on participants’ perception of their PCOS symptoms. An alternative explanation is that the 
PCOSQ (Barnard et al., 1997) is not sufficiently sensitive to the psychological impact of PCOS, 
and a more sensitive alternative needs to be developed.
The present study found a statistically significant improvement in anxiety from baseline to 
Week 6, demonstrating an improvement from mild anxiety to almost normal levels. Depression 
scores also significantly reduced – albeit within the normal range – from baseline to Week 6, 
and from baseline to follow-up.
The results of the present study are unlikely to have been influenced by circadian rhythms 
because the blood samples, taken pre and post the relaxation session, were taken within 
an hour of each other, and at roughly the same time of the evening on each measurement 
occasion for each participant. Furthermore, DHEAS and androstenedione are relatively stable 
throughout the day, and cortisol levels are relatively stable in the early evening, which is when 
the serum samples were taken (Young et al., 2001; also Ostrowska et al., 1998).
Despite the small sample size and lack of control group, this pilot study has several strengths. 
The assay method used to measure hormones was liquid chromatography tandem mass 
spectrometry, the gold standard methodology for measuring testosterone at the low levels seen 
in women, which gives us confidence that the hormone levels found were assessed accurately. 
Although the main potential confounding variables (individual differences, medication use) were 
eliminated by the repeated measures design and stability of medication use, there is of course the 
possibility that – despite the intervention occurring at the same time of day for each participant 
on each measurement occasion – the results were due to chance variations in hormone levels, 
or some other unknown factor. The group was relatively homogenous in having similar age and 
BMI. The lack of correlation between life-change unit (LCU) scores and the outcomes across all 
measurement occasions suggests that stressful life events were not related to outcomes. The 
fact that the participants were taking medication commonly used by women with PCOS makes 
the findings generalizable to the average woman with PCOS.
This is the first paper to report a psychological intervention for women with PCOS which 
causes a significant reduction in adrenal androgen levels. The reductions were generally 
modest, and in the absense of other information we must speculate that, given that androgen 
sensitivity is likely to be subject to individual differences (Wang & Zane, 2008), the physiological 
impact will vary from person to person. The intervention we used was minimal in order that 
the programme could be relatively inexpensive to deliver and easy for other research groups to 
replicate. The effects found in this pilot study might be increased by extending the duration of 
the intervention (e.g. to 30 minutes), and having more frequent sessions (e.g. two per week). 
As a next step, a future study should use a larger sample size and a randomized controlled trial 
design, and assess changes to physiological outcomes such as menstrual functioning and BMI.
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